TerminatedPhase 2

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

Stopped: Did not achieve statistical significance for primary endpoint

United States102 participantsStarted 2011-11-02

Plain-language summary

The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female patients ≥18 years old
✓. Patients with Stage IV or Stage V chronic kidney disease who will receive a kidney transplant from a living donor to whom they are sensitized and require desensitization prior to transplantation

Exclusion criteria

✕. ABO incompatible with living donor
✕. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient

What they're measuring

Treatment Failure Rate

Timeframe: 9 weeks post-transplantation

Trial details

NCT IDNCT01399593

SponsorAlexion Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2014-05-13

Results submitted2017-03-09

View on ClinicalTrials.gov More Antibody Mediated Rejection trials